Delocamten is the inhibitor for cardiac myosin with an IC50 of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction.

Adhibin is an allosteric inhibitor for RhoGAP class IX myosin, that inhibits Myo9 ATPase in mammalian and invertebrate with IC50 of 2.5 µM and 2.6 µM. Adhibin binds to the ATPase of myosin, interfers with its motor function, blocks the RhoGTPase related signaling pathway, and affects the cell migration, adhesion and cell division. Adhibin can be used in research about cancer metastasis.

(S)-3'-Hydroxy blebbistatin is a myosin II inhibitor and is more water-soluble than Blebbistatin.

(S)-3'-Aminoblebbistatin is the derivative of Blebbistatin.

SPA107 (Hemiasterlin methyl ester) is a Hemiasterlin.

Myoseverin B is a microtubule assembly inhibitor capable of inhibiting the polymerization of tubulin (IC50 = 2 μM) and exhibiting low cytotoxicity in most cell types. Myoseverin B can be used in research as an antitumor agent.

JC168 is a phenyl analog of peloruside and serves as a microtubule inhibitor, demonstrating antiproliferative and anticancer activities. JC168 promotes tubulin polymerization, thereby interfering with microtubule dynamics, and can be utilized in research related to microtubule-associated disorders.

Icafolin-methyl is a plant-specific herbicide and an inhibitor of tubulin polymerization. It is metabolized to carboxylic acid icafolin in plants, potentially inhibiting tubulin polymerization by binding to β-tubulin.

Ethaboxam is a β-tubulin inhibitor that can be used as anti-oomycete fungicide.

DPP-21 is an inhibitor of tubulin polymerization (IC50: 2.4 μM). DPP-21 shows anti-proliferative activity against cancer cell lines, with IC50s of 0.38 nM (HCT116), 11.69 nM (B16), 5.37 nM (HeLa), 9.53 nM (MCF7), 8.94 nM (H23) and 9.37 nM (HepG2) respectively. DPP-21 arrests the cell cycle in the G2/M phase of mitosis, subsequently inducing tumor cell apoptosis (decreases Bcl-2 but upregulates the pro-apoptotic protein Bax).

cis-9,10-Dehydroepothilone D (KOS-1584) is an epothilone derivative with antiproliferative activity and tubulin polymerization activity. cis-9,10-Dehydroepothilone D can be used for the study of lung cancer, colon cancer, prostate cancer and breast cancer.

BKS3031A is the inhibitor for αβ-tubulin that binds to the colchicine binding site, and inhibits the microtubule assembly dynamics.

AB8939 is an effective small moleculeMicrotubule/Tubulin polymerization inhibitor with anti-tumor activity (it inhibits tumor cell proliferation with an IC50 of less than 10 nM). AB8939 can effectively evade resistance mechanisms mediated by things like P-glycoprotein and myeloperoxidase. AB8939 can induce G2/M phase cell cycle arrest and apoptosis in cells.

7-Acetyl paclitaxel is a microtubule depolymerization inhibitor which inhibits calcium-induced microtubule depolymerization. 7-Acetyl paclitaxel reduces the growth of J774.2 macrophages (IC50 ~ 60 nM) and increases the levels of nitric oxide (NO) and TNF in isolated mouse peritoneal macrophages.

(S)-AM-9022 is the S-enantiomer of AM-9022. 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO can be utilized in AUTAC synthesis.

K34c hydrochloride is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c hydrochloride reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c hydrochloride can be used in glioblastoma research.

EMD-132338 is a GPIIb/IIIa (αIIbβ3) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research.

Des-ethyl-carafiban (Compound 44) is a fibrinogen receptor antagonist that can effectively inhibit platelet aggregation induced by multiple agonists. Des-ethyl-carafiban can be used in the research of thrombotic diseases.

Carotegrast methyl (AJM300) hydrochloride is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl hydrochloride, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl hydrochloride prevents the development of colitis in mice.

GB2095 is a selective, orally active inhibitor for galectin-3 with Kd of 36 nM and 0.35 μM for human galectin-3 and mouse galectin-3. GB2095 exhibits antitumor efficacy in mouse models.

Eribulin Mesylate (E7389 Mesylate), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules.

AM-1882 (AM1882) is a potent, selective mitotic kinesin KIF18A inhibitor with IC50 of 230 nM in kinesin-8 microtubule (MT)-ATPase motor assays.

​​THI0019​​ represents a novel class of integrin modulators with unique agonist activity targeting multiple adhesion receptors.

AM-5308 is a potent and selective KIF18A inhibitor with demonstrated antitumor activity in cell-based and animal models. Its ability to disrupt mitosis and induce cancer cell death makes it a promising candidate for further development as a cancer therapeutic.

Mavacamten（MYK-461）is a small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain.

CK-636(CK-0944636) is a small molecule inhibitor of Arp2/3 complex; Inhibitor of actin polymerization; Cell permeable inhibitor of human (IC50=4μM), fission yeast (IC50=24μM) and bovine (IC50=32μM) Arp2/3 complex between Arp2 and Arp3.

SB-216 is a potent tubulin polymerization inhibitor. SB-216 shows strong antiproliferative potency in a panel of human cancer cell lines, including melanoma, lung cancer, and breast cancer.  SB-216 can be used for cancer research.

GSK3335103 is a highly potent and orally bioavailable nonpeptidic αvβ6 integrin inhibitor with pIC50 of 8.0. GSK3335103 shows high desirable oral pharmacokinetic profiles in rat, dog, and minipig, with low to moderate clearance, moderate volumes of distributio, high to complete oral bioavailabilities and high solubility in all physiological media.

FiVe1 is a vimentin binding small molecule that promotes vimentin disorganization and phosphorylation during metaphase, causes mitotic catastrophe, multinucleation, and the loss of stemness in cancer cells.

AM-9022 (AM9022) is a potent, selective and orally active mitotic kinesin KIF18A inhibitor with IC50 of 47 nM in kinesin-8 microtubule (MT)-ATPase motor assays.